Biopharmaceutical
We are committed to discovering and developing medicines that improve the well being of people at every stage of their lives. We are proud of our cutting-edge portfolio of medicines for therapeutic areas such as pain, acute infection, cardiovascular diseases, oncology, ophthalmology, urology, female and mental health. With the acquisition of Wyeth in 2009, Pfizer has expanded into the vaccines business and is currently the market leader for pneumococcal conjugate vaccines.
More children in Singapore enjoy protection against pneumonia, meningitis and other related complications, thanks to the inclusion of pneumococcal vaccination in the National Childhood Immunisation Programme in 2009 by the Ministry of Health.
In line with the Singapore’s government philosophy of a healthy lifestyle through disease prevention, Pfizer has been at the forefront to promote public health through public education programmes in partnership with non-governmental organizations and healthcare providers.